Alumis reported that its TYK2 inhibitor failed to meet efficacy goals in a mid-stage lupus trial, dealing a setback to its lead development program. A separate report of the same event says the phase 2b lupus study missed both primary and secondary endpoints for envudeucitinib, but Alumis indicated it still sees a path to phase 3 by moving forward based on evidence in a prespecified subgroup. For biotech investors and competitors, the key watch items are whether the phase 2 signal in that subgroup can be replicated, and whether safety and biomarker readouts remain consistent across trial populations. The development also raises the bar for future TYK2 launches in systemic lupus, where heterogeneity and endpoint sensitivity continue to drive trial outcomes.